Evaluating the trial design, data quality, and clinical significance of Phase 3 clinical trials is too difficult for ordinary investors. Let professional journal editors help us evaluate. 0. Left side move away: In many cases, there is a lag from when pharmaceutical companies announce the basic results of clinical trials to when the specific content of the clinical trials and the papers are published, which can take weeks to months, including revisions to the details and discussion sections of the papers, as well as the journal's scheduling, etc...